Stem Cell IP Report Negative on Royalty Sharing, Favorable Pricing
A prestigious California advisory group today looked askance at proposals for royalty revenue sharing involving the California stem cell agency and was less than excited about "favorable pricing" for any therapies that might be developed.
Sharing revenues could be a disincentive to recipients of grants, both from the private and non-profit sector. Feder…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.